Talaris Therapeutics, Inc. (TALS)

NASDAQ: TALS · IEX Real-Time Price · USD
2.47
+0.01 (0.41%)
Sep 27, 2022 4:00 PM EDT - Market closed
0.41%
Market Cap 101.63M
Revenue (ttm) n/a
Net Income (ttm) -63.54M
Shares Out 41.15M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 155,040
Open 2.45
Previous Close 2.46
Day's Range 2.34 - 2.53
52-Week Range 2.04 - 17.49
Beta n/a
Analysts Buy
Price Target 14.28 (+478.1%)
Earnings Date Aug 11, 2022

About TALS

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 i... [Read more...]

Industry Biotechnology
IPO Date May 7, 2021
Employees 128
Stock Exchange NASDAQ
Ticker Symbol TALS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TALS stock is "Buy." The 12-month stock price forecast is 14.28, which is an increase of 478.14% from the latest price.

Price Target
$14.28
(478.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant ...

BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform ...

6 days ago - GlobeNewsWire

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

3 weeks ago - GlobeNewsWire

Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed a...

1 month ago - GlobeNewsWire

Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

BOSTON and LOUISVILLE, Ky., June 30, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

2 months ago - GlobeNewsWire

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

BOSTON and LOUISVILLE, Ky., June 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

3 months ago - GlobeNewsWire

Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) a...

BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

3 months ago - GlobeNewsWire

Talaris Therapeutics to Present at the Jefferies Healthcare Conference

BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform th...

3 months ago - GlobeNewsWire

Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform th...

4 months ago - GlobeNewsWire

Talaris Therapeutics Announces Changes to Board of Directors

BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform th...

4 months ago - GlobeNewsWire

Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update

Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients

4 months ago - GlobeNewsWire

Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress

BOSTON and LOUISVILLE, Ky., May 02, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform th...

4 months ago - GlobeNewsWire

Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001

Low rate of COVID-19 infection observed in vaccinated, durably  chimeric patients off immunosuppression

5 months ago - GlobeNewsWire

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform ...

6 months ago - GlobeNewsWire

Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results

Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022

6 months ago - GlobeNewsWire

Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

7 months ago - GlobeNewsWire

Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

8 months ago - GlobeNewsWire

Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

8 months ago - GlobeNewsWire

Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index

BOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform ...

9 months ago - GlobeNewsWire

Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Tra...

Analysis confirms FCR001 induced durable tolerance in highly mismatched related and unrelated recipients Analysis confirms FCR001 induced durable tolerance in highly mismatched related and unrelated rec...

9 months ago - GlobeNewsWire

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Sc...

FREEDOM-3 trial will evaluate the safety and efficacy of the company's investigational allogeneic cell therapy, FCR001, to treat severe cases of diffuse cutaneous systemic sclerosis (dcSSc) FREEDOM-3 tr...

9 months ago - GlobeNewsWire

Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients

10 months ago - GlobeNewsWire

Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

10 months ago - GlobeNewsWire

Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analys...

BOSTON and LOUISVILLE, Ky., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today provided the first clinical update on its Phase...

10 months ago - GlobeNewsWire

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction

FREEDOM-2 trial will evaluate the potential for the company's investigational allogeneic cell therapy, FCR001, to induce durable immune tolerance in patients who have previously received a kidney from a...

10 months ago - GlobeNewsWire

Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrol...

BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the Am...

10 months ago - GlobeNewsWire